Market Overview

UPDATE: Morgan Stanley Reiterates On PHH On Multiple Value Drivers

Share:

In a report published Tuesday, Morgan Stanley analyst Cheryl M. Pate reiterated an Equal-Weight rating on PHH (NYSE: PHH), and raised the price target from $23.00 to $24.00.

In the report, Morgan Stanley noted, “We have updated our model and estimates for the announced fleet sale. Though the exact usage of excess cash remains uncertain, we assume PHH will employ a combination of alternatives. In our base case, we assume the remainder of the 2016 debt is repaid in 4Q14 (following the repayment of the 2014 notes in September) and PHH begins a buyback in 4Q14, in addition to supporting growth in the mortgage businesses. We increase our price target by $1 to $24, based on PHH's pro forma balance sheet.”

PHH closed on Monday at $23.01.

Latest Ratings for PHH

DateFirmActionFromTo
Jun 2017DowngradesOutperformNeutral
Mar 2017UpgradesNeutralOutperform
Oct 2016Initiates Coverage OnNeutral

View More Analyst Ratings for PHH
View the Latest Analyst Ratings

Posted-In: Cheryl M. Pate Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Related Articles (PHH)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
ARAVH.C. WainwrightReiterates31.0
QCOMCascendReiterates110.0
KMPHH.C. WainwrightReiterates2.5
HASusquehannaInitiates Coverage On27.0
BFRABenchmarkMaintains18.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

UPDATE: Morgan Stanley Assumes Coverage Of Netflix, Bullish On U.S. Business

Merrimack Pharma Will Present Added Data Results in Phase 3 NAPOLI-q Study at ESMO